Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Landscape of Circulating Tumor DNA (ctDNA) in Appendiceal Adenocarcinoma.
White MG, Zeineddine MA, Fallon EA, Zeineddine FA, Dansby J, Chowdhury S, Hornstein N, Yousef A, Yousef M, Bhutiani N, Gu Y, Kee B, Dasari A, Overman MJ, Raghav K, Kopetz S, Uppal A, Taggart M, Newhook T, Fournier K, Helmink B, Drusbosky LM, Shen JP. White MG, et al. Among authors: raghav k. Clin Cancer Res. 2024 Dec 16. doi: 10.1158/1078-0432.CCR-24-2474. Online ahead of print. Clin Cancer Res. 2024. PMID: 39679931
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: raghav k. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Nat Commun. 2024. PMID: 39587050 Free PMC article. Clinical Trial.
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.
De B, Dogra P, Zaid M, Elganainy D, Sun K, Amer AM, Wang C, Rooney MK, Chang E, Kang HC, Wang Z, Bhosale P, Odisio BC, Newhook TE, Tzeng CD, Cao HST, Chun YS, Vauthey JN, Lee SS, Kaseb A, Raghav K, Javle M, Minsky BD, Noticewala SS, Holliday EB, Smith GL, Koong AC, Das P, Cristini V, Ludmir EB, Koay EJ. De B, et al. Among authors: raghav k. medRxiv [Preprint]. 2024 Sep 12:2024.09.11.24313334. doi: 10.1101/2024.09.11.24313334. medRxiv. 2024. PMID: 39314943 Free PMC article. Preprint.
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Yousef M, et al. Among authors: raghav kp. JAMA Oncol. 2024 Nov 1;10(11):1519-1529. doi: 10.1001/jamaoncol.2024.3666. JAMA Oncol. 2024. PMID: 39264607
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Raghav K, et al. Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5. Lancet Oncol. 2024. PMID: 39116902 Clinical Trial.
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Piha-Paul SA, et al. Among authors: raghav kp. NPJ Precis Oncol. 2024 Jul 31;8(1):166. doi: 10.1038/s41698-024-00634-6. NPJ Precis Oncol. 2024. PMID: 39085400 Free PMC article.
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.
Hornstein NJ, Zeineddine MA, Gunes BB, Pellatt AJ, Knafl M, Zhu H, Willett AF, Yousef A, Liu S, Sun R, Futreal A, Woodman SE, Taggart MW, Overman MJ, Halperin DM, Raghav KP, Shen JP. Hornstein NJ, et al. Among authors: raghav kp. Cancer Res Commun. 2024 May 29;4(5):1363-1368. doi: 10.1158/2767-9764.CRC-24-0019. Cancer Res Commun. 2024. PMID: 38709066 Free PMC article. Clinical Trial.
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP. Yousef A, et al. Among authors: raghav kp. JAMA Netw Open. 2024 Feb 5;7(2):e240260. doi: 10.1001/jamanetworkopen.2024.0260. JAMA Netw Open. 2024. PMID: 38416491 Free PMC article.
161 results